"Men"

Brigham and Women's Hospital (formerly Brigham and Women's Hospital), also known as Brigham and Women's Hospital, has a long history and is the second largest hospital affiliated with Harvard Medical School in the United States. Hospital (founded in 1832), which merged in 1980

This is the best way to prevent blood clots.

Pancreatic cancer has long been known as the "king of cancers" due to its poor prognosis. However, a recent study showed that adding Mitazalimab to a modified FOLFIRINOX regimen resulted in control of over 90% of patients with metastatic pancreatic cancer, with 52% of patients experiencing significant tumour shrinkage!

Nasopharyngeal cancer is a very complex disease that causes abnormal symptoms in the ears and nose, which can seriously affect the health and living conditions of patients with nasopharyngeal cancer.

Every September is the "World Alzheimer's Disease Month". In 2022, the theme of "World Alzheimer's Disease Month" is "Know Dementia, Know Alzheimer's - Another, we can do so much". It aims to continue to focus on early screening and early diagnosis, and focus on publicizing the 10 early symptoms, 12 risk factors that can be intervened and medical and social support after diagnosis of Alzheimer's disease, so as to achieve the goal of overall management of Alzheimer's disease

To prevent dry skin, roughness and constipation, you should also pay attention to diet and nutrition. Vitamin A has the role of promoting epithelial growth and protecting the skin, so eat more carrots and green leafy vegetables and beans containing vitamin A in autumn.

According to data from a phase 2 trial, the new treatment Tovorafenib resulted in significant tumour shrinkage in 64% of patients with low-grade gliomas in children, a clinical benefit rate of 91%.

Results from a pivotal phase 3 trial show that the PD-1 therapy Keytruda, in combination with chemotherapy, significantly improves survival in patients with advanced gastric cancer and has a favorable safety profile. Patients benefited regardless of their PD-L1 expression.

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!

Most of the time, uterine cold is caused by too much cold energy in the body.